 HAMILTON, ON and BOSTON, July 28, 2021 PRNewswire -- Fusion Pharmaceuticals Inc. Nasdaq: FUSN, a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the U.S. Food and Drug Administration FDA has cleared the Companys Investigational New Drug IND applications for 225Ac-FPI-1966 FPI-1966 and imaging agent 111In-FPI-1967 FPI-1967. FPI-1966 is a targeted alpha therapy TAT designed to use vofatamab, a human monoclonal antibody, to target and deliver actinium-225 to tumor sites expressing fibroblast growth factor 3 FGFR3, a protein that is overexpressed in multiple tumor types, particularly head and neck and bladder cancers. 